This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Investors Buy Eli Lilly's (LLY) Stock After Strong Q2 Results?
by Shaun Pruitt
As one of the largest pharmaceutical companies, Eli Lilly (LLY) said its growth trajectory accelerated during Q2 as its medicines are reaching more people worldwide.
5 ETFs to Make the Most of Eli Lilly's Strength
by Sweta Killa
Impressed by Eli Lilly's (LLY) blowout earnings, several analysts raised their target price on the stock.
International Markets and Lilly (LLY): A Deep Dive for Investors
by Zacks Equity Research
Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.
Company News for Aug 9, 2024
by Zacks Equity Research
Companies in The News Are: CYBR, PH, LLY, DDOG
Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day
Eli Lilly: The Next $1 Trillion Market Cap Stock?
by Ethan Feller
Eli Lilly showcased the exceptional strength of its business during its quarterly earnings meeting on Thursday morning
Eli Lilly (LLY) Q2 Earnings Top, Mounjaro, Zepbound Drive View
by Zacks Equity Research
Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
Continuing Claims Hit Highest Since Nov 2021
by Zacks Equity Research
Continuing Claims Hit Highest Since Nov 2021
Jobless Claims Decline, Pre-Markets in the Green
by Zacks Equity Research
It???s a big day for Wall Street as the much-awaited Jobless Claims numbers are out, which could be a major factor in market moves for the rest of the week.
Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Eli Lilly (LLY) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 48.48% and 14.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024. Stock falls.
Eli Lilly (LLY) & Novo Nordisk (NVO) Earnings: A Closer Look
by Derek Lewis
Given their underperformance in 2024, a positive set of quarterly results could easily push both stocks higher.
Can Mounjaro & Zepbound Drive Eli Lilly (LLY) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Kanishka Das
Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?
by Kinjel Shah
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
Lilly (LLY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Company News for Aug 2, 2024
by Zacks Equity Research
Companies In The Article Are: LLY,MGM,SO and TRP
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.